Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2',3'-deoxyadenosine + H2O
2',3'-deoxyinosine + NH3
-
1.7% of the activity with adenosine
-
-
?
2',3'-dideoxyadenosine + H2O
2',3'-dideoxyinosine + NH3
2',3'-isopropylideneadenosine + H2O
2',3'-isopropylideneinosine + NH3
2',3'-O-isopropylidenadenosine + H2O
2',3'-O-isopropylideninosine + NH3
modeling studies
-
-
?
2',3'-O-isopropylidene adenosine + H2O
2',3'-O-isopropylidene inosine + NH3
-
-
-
-
?
2',3'-O-methoxymethylideneadenosine + H2O
2',3'-O-methoxymethylideneinosine + NH3
modeling studies
-
-
?
2'-dAMP + H2O
2'-dIMP + NH3
-
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
2'-deoxyguanosine + H2O
2'-deoxyxanthosine + NH3
-
ADAII shows 41% of the activity with adenosine
-
-
?
2,6-diaminopurine arabinoside + H2O
arabinoguanosine + NH3
-
-
-
-
?
2,6-diaminopurine riboside + H2O
guanosine + NH3
-
-
-
-
?
2,6-diaminopurine-2',3'-dideoxyriboside + H2O
2',3'-dideoxyguanosine + NH3
-
-
-
-
?
2,6-diaminopurine-2'-deoxyriboside + H2O
2'-deoxyguanosine + NH3
-
-
-
-
?
2-amino-6-chloropurine riboside + H2O
guanosine + ?
-
-
-
-
?
2-amino-6-chloropurine riboside + H2O
guanosine + Cl-
Micrococcus sodonensis
-
-
-
?
2-amino-6-methoxypurine riboside + H2O
guanosine + ?
-
-
-
-
?
3'-deoxyadenosine + H2O
3'-deoxyinosine + NH3
5'-AMP + H2O
5'-IMP + NH3
5'-methylthioadenosine + H2O
5'-methylthioinosine + NH3
6-chloropurine riboside + H2O
inosine + Cl-
6-chloropurinriboside + H2O
inosine + Cl-
-
-
-
-
?
6-methoxypurinriboside
?
-
-
-
-
?
6-methylaminopurine ribonucleoside + H2O
inosine + methylamine
-
-
-
-
?
adenine + H2O
? + NH3
-
-
-
?
adenine + H2O
hypoxanthine + NH3
adenine arabinoside + H2O
inosine arabinoside + NH3
adenosine + H2O
inosine + NH3
adenosine 3'-monophosphate + H2O
inosine 3'-monophosphate + NH3
56% of the activity of adenine
-
-
?
adenosine 3'-phosphate + H2O
inosine 3'-phosphate + NH3
adenosine-3'-monophosphate + H2O
IMP-3'-monophosphate + NH3
arabinoadenosine + H2O
arabinoinosine + NH3
-
-
-
-
?
double-stranded RNA + H2O
?
-
-
-
-
?
formycin A + H2O
2-(hydroxymethyl)-5-(1H-pyrazolo[4,3-d]pyrimidin-3-yl)tetrahydrofuran-3,4-diol + NH3
guanine + H2O
xanthine + NH3
-
ADAII shows 47% of the activity with adenosine
-
-
?
guanosine + H2O
xanthosine + NH3
-
ADAII shows 75% of the activity with adenosine
-
-
?
N6-isopentenyladenosine + H2O
?
1.9% of the activity of adenine
-
-
?
N6-isopentenyladenosine + H2O
inosine + 3-methylbut-3-en-1-amine
1.2% of the activity of adenine
-
-
?
viramidine + H2O
ribavirin + NH3
additional information
?
-
2',3'-dideoxyadenosine + H2O
2',3'-dideoxyinosine + NH3
-
-
-
-
?
2',3'-dideoxyadenosine + H2O
2',3'-dideoxyinosine + NH3
-
-
-
-
?
2',3'-isopropylideneadenosine + H2O
2',3'-isopropylideneinosine + NH3
Micrococcus sodonensis
-
-
-
?
2',3'-isopropylideneadenosine + H2O
2',3'-isopropylideneinosine + NH3
-
-
-
ir
2',3'-isopropylideneadenosine + H2O
2',3'-isopropylideneinosine + NH3
-
-
-
ir
2',3'-isopropylideneadenosine + H2O
2',3'-isopropylideneinosine + NH3
-
-
-
?
2',3'-isopropylideneadenosine + H2O
2',3'-isopropylideneinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
ir
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
ir
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
ADAII shows 88% of the activity with adenosine
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
ir
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
118.9% of the activity with adenosine
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
79.2% of the activity with adenosine
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
ir
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
82.8% of the activity with adenosine
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
the enzyme plays an important role in the immune system
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
Micrococcus sodonensis
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
ir
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
ir
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
ir
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
ir
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
?
2'-deoxyadenosine + H2O
2'-deoxyinosine + NH3
-
-
-
-
?
3'-deoxyadenosine + H2O
3'-deoxyinosine + NH3
-
-
-
?
3'-deoxyadenosine + H2O
3'-deoxyinosine + NH3
-
2.4% of the activity with adenosine
-
-
?
3'-deoxyadenosine + H2O
3'-deoxyinosine + NH3
Micrococcus sodonensis
-
-
-
?
5'-AMP + H2O
5'-IMP + NH3
-
1.4% of the activity with adenosine
-
-
?
5'-AMP + H2O
5'-IMP + NH3
-
-
-
-
?
5'-AMP + H2O
5'-IMP + NH3
-
-
-
-
ir
5'-AMP + H2O
5'-IMP + NH3
-
-
-
-
ir
5'-AMP + H2O
5'-IMP + NH3
-
-
-
-
?
5'-AMP + H2O
5'-IMP + NH3
-
-
-
-
?
5'-methylthioadenosine + H2O
5'-methylthioinosine + NH3
-
-
-
-
?
5'-methylthioadenosine + H2O
5'-methylthioinosine + NH3
-
-
-
-
?
5'-methylthioadenosine + H2O
5'-methylthioinosine + NH3
-
-
-
-
?
5'-methylthioadenosine + H2O
5'-methylthioinosine + NH3
-
-
-
ir
5'-methylthioadenosine + H2O
5'-methylthioinosine + NH3
-
-
-
-
?
5'-methylthioadenosine + H2O
5'-methylthioinosine + NH3
-
-
-
-
?
5'-methylthioadenosine + H2O
5'-methylthioinosine + NH3
-
-
-
ir
5'-methylthioadenosine + H2O
5'-methylthioinosine + NH3
adenosine deaminase has a secondary function in recycling methylthiopurines from the polyamine biosynthetic pathway
-
-
ir
6-chloropurine riboside + H2O
inosine + Cl-
-
-
-
-
?
6-chloropurine riboside + H2O
inosine + Cl-
-
-
-
-
?
6-chloropurine riboside + H2O
inosine + Cl-
Micrococcus sodonensis
-
-
-
?
adenine + H2O
hypoxanthine + NH3
-
-
-
-
?
adenine + H2O
hypoxanthine + NH3
-
ADAII shows 70% of the activity with adenosine
-
-
?
adenine + H2O
hypoxanthine + NH3
-
-
-
?
adenine arabinoside + H2O
inosine arabinoside + NH3
-
-
-
-
?
adenine arabinoside + H2O
inosine arabinoside + NH3
-
-
-
-
?
adenine arabinoside + H2O
inosine arabinoside + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
30% of the activity of adenine
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
key enzyme in controlling intra- and extracellular adenosine levels
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
ir
adenosine + H2O
inosine + NH3
key enzyme involved in the purine metabolism
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
preferred substrate
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
655265, 667870, 668232, 668751, 670393, 670464, 686745, 687290, 697368, 697735, 699651, 699959, 699972, 733602, 733674 -
-
?
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
isozyme ADA2 is important in lymphocyte activation, and may be active in sites of inflammation and during hypoxia and in areas of tumor growth with elevated adenosine levels and acidic pH, overview
-
-
?
adenosine + H2O
inosine + NH3
-
the enzyme activity is correlated with the content in malonaldehyde in nasal polyps and nasal mucosa, overview
-
-
?
adenosine + H2O
inosine + NH3
-
the enzyme expression and activity is suppressed in normal pregnancy, but not in woman with recurrent spontaneous abortion
-
-
?
adenosine + H2O
inosine + NH3
-
the enzyme is involved in differentiation and maturation of the lymphoid system, the enzyme activity is decreased in multiple sclerosis patients irrespective of whether patients have relapsing-remitting or chronic progressive multiple sclerosis, overview
-
-
?
adenosine + H2O
inosine + NH3
-
the enzyme plays an important role in the immune system
-
-
?
adenosine + H2O
inosine + NH3
-
metabolization of extracellular adenosine leads to exacerbation of inflammation
-
-
ir
adenosine + H2O
inosine + NH3
-
detailed quantitative structure-activity relationship, QSAR, nonlinear modeling and analysis, descriptor generation and selection, overview
-
-
?
adenosine + H2O
inosine + NH3
-
metabolization of extracellular adenosine
-
-
ir
adenosine + H2O
inosine + NH3
-
adenosine deaminase markedly enhances the agonist and antagonist affinity and abolishes the negative cooperativity on agonist binding to human striatial adenosine A1 receptors
-
-
?
adenosine + H2O
inosine + NH3
the enzyme shows no activity with 5'-methylthioinosine
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
adenosine deaminase is involved in purine metabolism and is a key enzyme for the control of the cellular levels of adenosine
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
catalytic efficiency of the enzyme for 5'-deoxyadenosine is 1000fold higher than for S-methyl-5'-thioadenosine, and 10000fold hgher than with S-adenosyl-L-homocysteine or adenosine
-
-
?
adenosine + H2O
inosine + NH3
catalytic efficiency of the enzyme for 5'-deoxyadenosine is 1000fold higher than for S-methyl-5'-thioadenosine, and 10000fold hgher than with S-adenosyl-L-homocysteine or adenosine
-
-
?
adenosine + H2O
inosine + NH3
Micrococcus sodonensis
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
ir
adenosine + H2O
inosine + NH3
the enzyme is crucial for purine metabolism and normal immune competence
-
-
ir
adenosine + H2O
inosine + NH3
-
the enzyme is important in thymocyte development, especially in late stages, overview
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
the enzyme is important in thymocyte development, especially in late stages, overview
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
ir
adenosine + H2O
inosine + NH3
-
the enzyme is involved in the bile duct-inflammation and fibrosis caused chronic fascioliasis including an atrophy of the liver parenchyma and liver cirrhosis
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
adenosine deamination is involved in the essential pathway of purine salvage in Plasmodium falciparum, and inhibition of purine salvage results in parasite death
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
ADA, nucleotide metabolism
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
ir
adenosine + H2O
inosine + NH3
1.4% of the activity of adenine
-
-
?
adenosine + H2O
inosine + NH3
2.0% of the activity of adenine
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
ir
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine + H2O
inosine + NH3
-
-
-
-
?
adenosine 3'-phosphate + H2O
inosine 3'-phosphate + NH3
3.3% of the activity of adenine
-
-
?
adenosine 3'-phosphate + H2O
inosine 3'-phosphate + NH3
4.5% of the activity of adenine
-
-
?
adenosine-3'-monophosphate + H2O
IMP-3'-monophosphate + NH3
-
-
-
-
ir
adenosine-3'-monophosphate + H2O
IMP-3'-monophosphate + NH3
-
-
-
-
?
adenosine-3'-monophosphate + H2O
IMP-3'-monophosphate + NH3
-
-
-
-
?
ADP + H2O
5'-IDP + NH3
-
-
-
-
?
ADP + H2O
5'-IDP + NH3
-
-
-
-
ir
ADP + H2O
5'-IDP + NH3
-
-
-
-
ir
ATP + H2O
ITP + NH3
68% of the activity of adenine
-
-
?
ATP + H2O
ITP + NH3
-
-
-
-
?
ATP + H2O
ITP + NH3
-
-
-
-
ir
ATP + H2O
ITP + NH3
3.3% of the activity of adenine
-
-
?
ATP + H2O
ITP + NH3
3.3% of the activity of adenine
-
-
?
formycin A + H2O
2-(hydroxymethyl)-5-(1H-pyrazolo[4,3-d]pyrimidin-3-yl)tetrahydrofuran-3,4-diol + NH3
-
-
-
-
?
formycin A + H2O
2-(hydroxymethyl)-5-(1H-pyrazolo[4,3-d]pyrimidin-3-yl)tetrahydrofuran-3,4-diol + NH3
-
-
-
-
?
viramidine + H2O
ribavirin + NH3
-
the enzyme catalyzes viramidine deamination to ribavirin in vivo as a prodrug conversion to active drug, pharmacokinetic analysis, overview
-
-
?
viramidine + H2O
ribavirin + NH3
-
substrate and product determination by LC-MS
-
-
?
additional information
?
-
does not cleave cytokinins
-
-
?
additional information
?
-
-
does not cleave cytokinins
-
-
?
additional information
?
-
-
regulatory role of dipeptidyl peptidase IV on adenosine deaminase activity
-
-
?
additional information
?
-
-
the enzyme may facilitate catalysis via the formation of a stabilizing conformation at the reaction transition state
-
-
?
additional information
?
-
-
the enzyme is bound and complexed by the cell membraneous dipeptidyl peptidase IV, which is identical to the activated immune cell antigen CD26, playing a role in the immune system, overview
-
-
?
additional information
?
-
-
substrate specificities of the large and the small isozyme, overview
-
-
?
additional information
?
-
-
no activity with 5'-methylthioadenosine
-
-
?
additional information
?
-
-
adenosine deaminase inhibition enhances the efficiency of signal transduction and inotropic response mediated by A1 adenosine receptor in hyperthyroid guinea pig atrium via elevated intracellular adenosine levels, overview
-
-
?
additional information
?
-
-
the enzyme is involved in purine metabolism and plays an important role in the mechanism of the immune system
-
-
?
additional information
?
-
-
no activity with 2'-O-methyladenosine
-
-
?
additional information
?
-
-
no activity with 3'-deoxyadenosine, 2',3'-deoxyadenosine and 2'-O-methyladenosine
-
-
?
additional information
?
-
-
activity with 3'-deoxyadenosine, 2',3'-deoxyadenosine and 2'-O-methyladenosine is less than 0.5% of the activity with adenine
-
-
?
additional information
?
-
-
the large isozyme is bound and complexed by the cell membraneous dipeptidyl peptidase IV, which is identical to the activated immune cell antigen CD26, playing a role in the immune system, overview
-
-
?
additional information
?
-
-
substrate specificities of the large and the small isozyme, overview
-
-
?
additional information
?
-
-
no activity with 5'-methylthioadenosine
-
-
?
additional information
?
-
-
Plasmodium gallinaceum ADA does not have significant activity for 5'-methylthioadenosine
-
-
?
additional information
?
-
-
adenosine modulates the immune system and inhibits inflammation via reduction of cytokine biosynthesis and neutrophil functions, enzyme inhibition reduces inflammation in experimental colitis, overview
-
-
?
additional information
?
-
-
ADA is associated with the Galphai-3 protein-coupled A1 receptor
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(+)-erythro-9-(2-hydroxy-3-nonyl)adenine
(2S,3R)-3-(6-amino-9H-purin-9-yl)-5-[3-(trifluoromethyl)phenyl]pentan-2-ol
comopound shows suitable balance of potency, microsomal stability and demonstrates better pharmacokinetic properties as compared to (+)-erythro-9-(2-hydroxy-3-nonyl)adenine
(2S,3R)-3-(6-amino-9H-purin-9-yl)-5-[4-(trifluoromethyl)phenyl]pentan-2-ol
comopound shows suitable balance of potency, microsomal stability and demonstrates better pharmacokinetic properties as compared to (+)-erythro-9-(2-hydroxy-3-nonyl)adenine
(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol
-
-
1,6-Dihydro-6-(hydroxymethyl)purine riboside
-
-
1-(4-benzylphenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea
-
1-(4-fluorophenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea
-
1-(4-methoxyphenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea
-
1-(hydroxymethyl)nonyl methanesulfonate
-
-
1-(tert-butyldimethylsilanyloxy)-decan-2-ol
-
-
1-(tert-butyldimethylsilanyloxymethyl)nonyl methanesulfonate
-
-
1-alkyl-3-amino-4-pyrazolecarbonitriles
-
-
1-alkyl-4-aminopyrazolo[3,4d]pyrimidines
-
-
1-benzyl-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea
-
1-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
1-[(1R)-1-(hydroxymethyl)-3-(6-[[(1-methyl-1H-benzimidazol-2-yl)acetyl]amino]-1H-indol-1-yl)propyl]-1H-imidazole-4-carboxamide
-
1-[(1R)-1-(hydroxymethyl)-3-naphthalen-1-ylpropyl]-1H-imidazole-4-carboxamide
-
1-[(1R)-1-(hydroxymethyl)-3-phenylpropyl]-1H-imidazole-4-carboxamide
-
1-[(1R)-2-hydroxy-1-phenylethyl]-1H-imidazole-4-carboxamide
-
1-[(1R)-3-[6-(acetylamino)-1H-indol-1-yl]-1-(hydroxymethyl)propyl]-1H-imidazole-4-carboxamide
-
1-[(1R)-3-[6-(hexanoylamino)-1H-indol-1-yl]-1-(hydroxymethyl)propyl]-1H-imidazole-4-carboxamide
-
1-[(1R,2S)-2-hydroxy-1-(2-naphthalen-1-ylethyl)propyl]-1H-imidazole-4-carboxamide
-
1-[(2S,3R)-2,3-dihydroxycyclopentyl]-5-(1,3-thiazol-5-yl)pyrimidine-2,4(1H,3H)-dione
28% inhibition at 0.1 mM
1-[(2S,3R)-2,3-dihydroxycyclopentyl]-5-(furan-2-yl)pyrimidine-2,4(1H,3H)-dione
35% inhibition at 0.1 mM
1-[(2S,3R)-2,3-dihydroxycyclopentyl]-5-(thiophen-2-yl)pyrimidine-2,4(1H,3H)-dione
36% inhibition at 0.1 mM
1-[(3R,4S)-4-hydroxy-1-[3-(trifluoromethyl)phenyl]pentan-3-yl]-1H-imidazole-4-carboxamide
comopound shows suitable balance of potency, microsomal stability and demonstrates better pharmacokinetic properties as compared to (+)-erythro-9-(2-hydroxy-3-nonyl)adenine
1-[(4R,5S)-4,5-dihydroxycyclopent-2-en-1-yl]-5-(1,3-thiazol-5-yl)pyrimidine-2,4(1H,3H)-dione
49% inhibition at 0.1 mM
1-[(4R,5S)-4,5-dihydroxycyclopent-2-en-1-yl]-5-(furan-2-yl)pyrimidine-2,4(1H,3H)-dione
55% inhibition at 0.1 mM
1-[(4R,5S)-4,5-dihydroxycyclopent-2-en-1-yl]-5-(thiophen-2-yl)pyrimidine-2,4(1H,3H)-dione
48% inhibition at 0.1 mM
1-[(R)-1-hydroxy-4-(1-methyl-5-(3-phenylpropoxy)indol-3-yl)-2-butyl]imidazole-4-carboxamide
-
1-[(R)-1-hydroxy-4-(5-(3-phenylpropoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
1-[(R)-1-hydroxy-4-(6-(3-(1-methylbenzimidazol-2-yl)propionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
1-[(R)-1-hydroxy-4-(6-(3-(3-pyridyl)propionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
1-[(R)-1-hydroxy-4-(6-(3-(4-methoxyphenyl)propionylamino)indol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
1-[(R)-1-hydroxy-4-(6-(3-(4-methylphenyl)propionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
1-[(R)-1-hydroxy-4-(6-(3-phenylpropionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
1-[(R)-1-hydroxy-4-(6-(3-phenylpropoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
1-[(R)-1-hydroxy-4-(6-(4-(4-methylphenyl)butyrylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
1-[(R)-1-hydroxy-4-(6-(4-phenylbutoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
1-[(R)-1-hydroxy-4-(6-(4-phenylbutyrylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
1-[(R)-1-hydroxy-4-(6-(5-phenylvalerylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
1-[(R)-1-hydroxy-4-(6-(6-phenylhexanoylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
1-[(R)-4-(5-(3-(4-chlorophenyl)propoxyl)-1-methylindol-3-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
1-[(R)-4-(5-hexyloxy-1-methylindol-3-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
1-[(R)-4-(5-hexyloxyindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
1-[(R)-4-(6-(3-(4-chlorophenyl)propoxy)indol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
1-[(R)-4-(6-(3-benzylureido)indol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
1-[(R)-4-(6-acetylaminoindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
1-[(R)-4-(6-butoxyindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
1-[(R)-4-(6-hexanoylaminoindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
1-[(R)-4-(6-hexyloxyindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
1-[4-(dimethylamino)phenyl]-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea
-
1-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-3-(4-phenoxyphenyl)urea
-
1-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-3-phenylurea
-
1-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-3-[4-(trifluoromethyl)phenyl]urea
-
2',3'-o-isopropyliden adenosine
-
-
2'-deoxy-4-amino-1-(beta-D-ribofuranosyl)-3H-imidazo[4,5-d]pyridazin-7-(6H)-one
-
-
2'-deoxy-7-amino-1-(beta-D-ribofuranosyl)-1H-imidazo[4,5-d]pyridazin-4-(5H)-one
-
-
2'-deoxyformycin
-
50% inhibition of isozyme ADA2 at 0.09 mM
2,2,2-trifluoro-N-[7-chloro-5-methyl-3-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-yl]-acetamide
20% inhibition at 0.4 mM
2,2,2-trifluoro-N-[7-chloro-5-methyl-3-(beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-yl]acetamide
23% inhibition at 0.4 mM
2,6-diaminopurine sulfate
-
-
2-alkyl-4-aminopyrazolo[3,4d]pyrimidines
-
-
2-Amino-4-hydroxypteridine
-
-
3-amino-1-(2-hydroxy-3-nonyl)4-pyrazolecarbonitrile
-
-
3-amino-1-(2-keto-3-nonyl)4-pyrazolecarbonitrile
-
-
3-amino-1-beta-hydroxyalkyl-4-pyrazolecarbonitriles
-
-
3-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
4-acetylamino-2-decylpyrazolo[3,4d]pyrimidine
-
-
4-amino-1-(2-hydroxy-3-nonyl)pyrazolo[3,4d]pyrimidine
-
-
4-amino-1-(beta-D-ribofuranosyl)-3H-imidazo[4,5-d]pyridazin-7-(6H)-one
-
-
4-amino-1-(beta-hydroxyethyl)pyrazolo[3,4d]pyrimidine
-
-
4-amino-1-(beta-hydroxyoctyl)pyrazolo[3,4d]pyrimidine
-
-
4-amino-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine
-
i.e. APP
4-amino-2-decyl-6-phenylpyrazolo[3,4d]pyrimidine
-
-
4-amino-5-imidazole carboxamide-HCl
-
-
4-amino-5-imidazole carboxyamide ribonucleoside
-
-
4-aminopyridine
-
competitive inhibition
4-aminopyrimidine
-
competitive inhibition
4-fluoro-N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]benzamide
-
4-hydroxypyridine
-
competitive inhibition
4-methoxy-N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]benzamide
-
5'-methylthio-2'-deoxycoformycin
-
-
5-(beta-D-ribofuranosyl)-1H,5H-imidazo[4,5-b]pyrazolo[3,4-e]pyridine
25% inhibition at 0.4 mM
5-carbamimidoyl-1-(beta-D-ribofuranosyl)-1H-imidazole-4-carbohydrazide
-
-
5-methyl-3-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-amine
19% inhibition at 0.4 mM
5-methyl-3-(beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-amine
6% inhibition at 0.4 mM
5-methyl-6-nitro-3-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridine
31% inhibition at 0.4 mM
5-methyl-6-nitro-3-(beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridine
25% inhibition at 0.4 mM
6-fluoro-D,L-tryptophan
adenosine analogue, induces conformational changes inhibiting the enzyme, structural mechanism, overview
6-Methylmercaptopurine riboside
7,8-dihydro-1-p-methoxybenzyl-6H-6,7-dimethyl-8-propoxyimidazo[4,5-e][1,2,4]-triazepine
-
-
7,8-dihydro-1-p-methoxybenzyl-8-(2-methoxyethoxy)-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
-
7,8-dihydro-1-p-methoxybenzyl-8-(3-methylbenzyloxy)-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
-
7,8-dihydro-1-p-methoxybenzyl-8-(4-methoxybenzyloxy)-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
-
7,8-dihydro-8-ethoxy-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
-
7,8-dihydro-8-isopropoxy-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
-
7,8-dihydro-8-methoxy-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
-
7-(beta-D-ribofuranosyl)-1H,7H-imidazo[4,5-b]pyrazolo[3,4-e]pyridine
7% inhibition at 0.4 mM
7-amino-1-(beta-D-ribofuranosyl)-1H-imidazo[4,5-d]pyridazin-4-(5H)-one
-
-
7-chloro-5-methyl-3-(beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-amine
15% inhibition at 0.4 mM
8-butoxy-7,8-dihydro-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
-
9-(p-aminobenzyl)adenine
-
-
acetaminophen
-
competitive at 27°C, uncompetitive at 37°C
adenosine analogues
induce conformational changes inhibiting the enzyme, structural mechanism, overview
-
adenosine monosulfate
-
-
aminoxyacetic acid
Micrococcus sodonensis
-
-
aspirin
-
significantly decreases adenosine deaminase activity, the half-life of adenosine will be lengthened as a consequence of decreased adenosine deaminase activity
aza adenosine analogues
-
-
-
Ba2+
-
44% inhibition at 5 mM
basic histone proteins
-
-
-
caffeic acid phenethyl ester
-
reduces the enzyme activity in vivo, suppresses the induction of the enzyme by cisplatin in vivo
deaza adenosine analogues
-
-
-
diclofenac
-
competitive at 27°C, uncompetitive at 37°C
dodecyltrimethylammonium bromide
at low concentrations (approximately 0.1 mM), enzyme activity decreases, it increases at a slightly higher concentration (about 0.2 mM), and finally decreases again (about 0.3 mM), CD spectra of adenosine deaminase and DTAB, determination of helix content, MD calculations
epigallocatechin gallate
most abundant and biologically active ?avonoid present in green tea, strong competitive inhibitory activity
erythro-9-(2-hydroxy-3-nonyl)-3-deazaadenine
-
-
erythro-9-(2-hydroxy-3-nonyl)-adenine
erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride
erythro-9-(2-hydroxy-3-nonyl)adenine
erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride
ethanol
CD spectra of adenosine deaminase and EtOH, determination of helix content, MD calculations
FR234938
-
i.e. 1-((1R,2S)-2-hydroxy-1-(2-(1-naphthyl)ethyl)propyl)1H-imidazole-4-carboxamine, a non-nucleoside inhibitor, the inhibition is blocked by an A2a adenosine receptor antagonist
HgCl2
-
inhibition of ADA activity is observed in the soluble fraction at 0.005-0.25 mM HgCl2 (84.6-92.6% respectively), whereas inhibition occurs at 0.005-0.25 mM in membrane fractions (20.9-26% respectively). The inhibition is partially or fully abolished by 0.5 mM dithiothreitol or EDTA
IgG
-
anti adenosine deaminase
-
indole-3-acetic acid
-
the plant hormone decreases enzyme activity in hearts, but not in kidney and muscle
iodoacetamide
Micrococcus sodonensis
-
-
isosorbide mononitrate
-
significantly decreases adenosine deaminase activity, the half-life of adenosine will be lengthened as a consequence of decreased adenosine deaminase activity
kinetin
-
the plant hormone decreases enzyme activity in hearts, but not in kidney and muscle
methanol
MD calculations, discussion of effects
methylmercury
-
concentration 0.1, 1.0, 20 M, inhibits adenosine deaminase activity in 7- and 60-day-old rats in a concentration-dependent manner, glutathione (50 microM) and dithiothreitol (50 microM) prevent the reduction of adenosine deaminase activity both in cerebral cortex and hippocampus, garlic alcoholic extract (100 microg/ml) abolishes the reduction of adenosine deaminase
metoprolol
-
significantly decreases adenosine deaminase activity, the half-life of adenosine will be lengthened as a consequence of decreased adenosine deaminase activity
N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-2-phenylacetamide
-
N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-4-(trifluoromethyl)benzamide
-
N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]benzamide
-
Na2SO4
CD spectra of adenosine deaminase and Na2SO4, determination of helix content, MD calculations, discussion of effects
NaCl
MD calculations, discussion of effects
nebularine
i.e. 9-beta-D-ribofuranosylpurine, competitive inhibitor
p-chloromercuryphenylsulfonate
-
-
p-hydroxymercuribenzoic acid
-
-
Pb2+
Micrococcus sodonensis
-
-
phenylhydrazine
-
competitive inhibition
progesterone
-
progesterone decreases adenosine deaminase levels, adenosine deaminase levels show regional specificity with differences among the cerebral hemispheres, cerebellum, and brainstems structures
purine
-
competitive inhibition
simvastatin
-
inhibits ADA1 activity by 46.7%; significantly decreases adenosine deaminase activity, the half-life of adenosine will be lengthened as a consequence of decreased ADA activity
Sodium dodecyl sulfate
at low concentrations (approximately 0.1 mM) enzyme activity decreases, it increases at a slightly higher concentration (about 0.4 mM), and finally decreases again (about 0.55 mM), CD spectra of adenosine deaminase and SDS, determination of helix content, MD calculations
Sodium selenate
-
does not alter enzyme activity
(+)-erythro-9-(2-hydroxy-3-nonyl)adenine
-
(+)-erythro-9-(2-hydroxy-3-nonyl)adenine
specific inhibitor of ADA1
1-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
i.e. 1-dEHNA
1-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
i.e. 1-dEHNA
1-deazaadenosine
-
-
2'-deoxycoformycin
-
a natural product transition state analogue inhibitor
2'-deoxycoformycin
-
0.0015 nM, 50% inhibition
2'-deoxycoformycin
-
0.15 nM, 50% inhibition
2'-deoxycoformycin
-
0.0004 nM, 50% inhibition
2'-deoxycoformycin
-
a natural product transition state analogue inhibitor
2'-deoxycoformycin
-
a natural product transition state analogue inhibitor
2,6-diaminopurine
-
-
2-Aminopurine
-
competitive inhibition
3-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
i.e. 3-dEHNA
3-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
i.e. 3-dEHNA
3-deazaadenosine
-
-
5'-methylthiocoformycin
-
specific transition state analogue inhibitor of Plasmodium ADA
5'-methylthiocoformycin
-
specific transition state analogue inhibitor of Plasmodium ADA
5'-methylthiocoformycin
-
-
5'-methylthiocoformycin
-
specific transition state analogue inhibitor of Plasmodium ADA, 5'-methylthiocoformycin is a subnanomolar inhibitor of Plasmodium falciparum ADA and demonstrates more than 20000fold selectivity relative to human ADA
5'-methylthiocoformycin
-
poor inhibitor of Plasmodium gallinaceum ADA
5'-methylthiocoformycin
-
specific transition state analogue inhibitor of Plasmodium ADA
5'-methylthiocoformycin
-
specific transition state analogue inhibitor of Plasmodium ADA
6-methylamino riboside
-
-
6-methylamino riboside
-
-
6-Methylmercaptopurine riboside
-
-
6-Methylmercaptopurine riboside
-
-
adenine
-
-
adenine
-
competitive inhibition
Ag+
Micrococcus sodonensis
-
-
Ca2+
-
69% inhibition at 5 mM
Cd2+
-
-
coformycin
-
-
coformycin
-
a natural product transition state analogue inhibitor
coformycin
-
a natural product transition state analogue inhibitor
coformycin
complete inhibition of ADA2 at 1 mM
coformycin
-
powerful picomolar inhibitor of ADA
coformycin
-
powerful picomolar inhibitor of ADA
coformycin
-
a natural product transition state analogue inhibitor
coformycin
-
powerful picomolar inhibitor of ADA
coformycin
-
powerful picomolar inhibitor of ADA
coformycin
-
powerful picomolar inhibitor of ADA
coformycin
-
powerful picomolar inhibitor of ADA
cordycepin
-
-
corticosterone
inhibits the adenosine deaminase activity in an age- and region-specific manner
Cu2+
-
-
Cu2+
-
0.029 mM, 50% inhibition
Cu2+
-
81% inhibition at 5 mM
D-coformycin
-
powerful picomolar inhibitor of ADA
D-coformycin
-
powerful picomolar inhibitor of ADA
D-coformycin
-
powerful picomolar inhibitor of ADA
D-coformycin
-
powerful picomolar inhibitor of ADA
D-coformycin
-
powerful picomolar inhibitor of ADA
D-coformycin
-
powerful picomolar inhibitor of ADA
Deoxycoformycin
-
-
EDTA
-
-
EDTA
Micrococcus sodonensis
-
-
erythro-9-(2-hydroxy-3-nonyl)-adenine
-
-
erythro-9-(2-hydroxy-3-nonyl)-adenine
-
0.1 mM concentration, ADA2 is practically unaffected; 0.1 mM concentration, complete and reversible inhibition
erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride
-
0.4 nM, 50% inhibition
erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride
-
0.45 nM, 50% inhibition
erythro-9-(2-hydroxy-3-nonyl)adenine
-
i.e. EHNA
erythro-9-(2-hydroxy-3-nonyl)adenine
i.e. (+)-EHNA
erythro-9-(2-hydroxy-3-nonyl)adenine
-
-
erythro-9-(2-hydroxy-3-nonyl)adenine
-
erythro-9-(2-hydroxy-3-nonyl)adenine
-
-
erythro-9-(2-hydroxy-3-nonyl)adenine
-
EHNA 0.1mM
erythro-9-(2-hydroxy-3-nonyl)adenine
-
-
erythro-9-(2-hydroxy-3-nonyl)adenine
-
i.e. EHNA
erythro-9-(2-hydroxy-3-nonyl)adenine
i.e. EHNA
erythro-9-(2-hydroxy-3-nonyl)adenine
-
i.e. EHNA, specific for isozyme ADA1, no inhibition of isozyme ADA2
erythro-9-(2-hydroxy-3-nonyl)adenine
-
i.e. EHNA, specific for isozyme ADA1
erythro-9-(2-hydroxy-3-nonyl)adenine
-
i.e. EHNA
erythro-9-(2-hydroxy-3-nonyl)adenine
-
-
erythro-9-(2-hydroxy-3-nonyl)adenine
-
ADA-specific inhibitor, almost complete inhibition at 0.00005 mM
erythro-9-(2-hydroxy-3-nonyl)adenine
-
-
erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride
-
erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride
-
i.e. EHNA
guanosine
-
-
Hg2+
-
-
Hg2+
-
88% inhibition at 5 mM
Hg2+
Micrococcus sodonensis
-
-
Inosine
-
-
Inosine
-
competitive inhibition
Inosine
31% inhibition at 0.1 mM
iodoacetic acid
-
-
iodoacetic acid
Micrococcus sodonensis
-
-
Mg2+
-
0.055 mM, 50% inhibition
Mn2+
-
-
Mn2+
-
0.046 mM, 50% inhibition
Mn2+
-
85% inhibition at 5 mM
N-ethylmaleimide
Micrococcus sodonensis
-
-
Ni2+
-
61% inhibition at 5 mM
o-phenanthroline
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
Micrococcus sodonensis
-
-
p-chloromercuribenzoate
-
-
pentostatin
-
pentostatin
-
i.e. 2'-deoxycoformycin, a selective ADA inhibitor
pentostatin
-
i.e. (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
purine riboside
-
-
purine riboside
adenosine analogue, induces conformational changes inhibiting the enzyme, structural mechanism, overview
theophylline
-
-
Zn2+
-
decrease of 31.3% on adenosine deamination in membranes is observed in the presence of 5 mM Zn2+
Zn2+
-
65% inhibition at 5 mM
Zn2+
Micrococcus sodonensis
-
-
additional information
structure-based design, synthesis, and structure-activity relationship studies of non-nucleoside adenosine deaminase inhibitors, overview
-
additional information
-
molecular dynamic simulations of inhibitor-enzyme interaction, overview
-
additional information
-
no inhibition of the bovine enzyme by 5'-methylthiocoformycin and 5'-methylthio-2'-deoxycoformycin
-
additional information
-
cytotoxic effects of inhibitors against human breast cancer cell lines MCF-7 and MCF-10A
-
additional information
the trend of relative activity is directly proportional to helicity and inversely proportional to accessible surface area
-
additional information
-
no inhibition by erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride
-
additional information
-
no inhibition of the human enzyme by 5'-methylthiocoformycin and 5'-methylthio-2'-deoxycoformycin
-
additional information
-
strong inhibition by the traditional Chinese medicines Rhizoma Chuanxiong and Angelica sinensis
-
additional information
loss of activity precedes the global secondary and tertiary structure transition when the enzyme is exposed to denaturant, structural mechanism, overview
-
additional information
-
loss of activity precedes the global secondary and tertiary structure transition when the enzyme is exposed to denaturant, structural mechanism, overview
-
additional information
-
ADA1 activity is not changed significantly by aspirin, metoprolol, isosorbide mononitrate, and molsidominemolsidomine; molsidomine does not influence plasma adenosine deaminase activity significantly
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.29
2',3'-isopropylidene adenosine
-
-
0.004 - 0.56
2'-deoxyadenosine
0.0044 - 0.37605
5'-methylthioadenosine
0.31
6-Chloropurine riboside
-
-
0.277
6-chloropurinriboside
-
-
0.081
6-methoxypurinriboside
-
-
2
Adenosine-3'-monophosphate
-
-
additional information
additional information
-
0.004
2'-deoxyadenosine
-
-
0.016
2'-deoxyadenosine
-
-
0.034
2'-deoxyadenosine
-
-
0.034
2'-deoxyadenosine
-
pH 7.4, 37°C
0.039
2'-deoxyadenosine
-
kidney cortex large isozyme
0.04
2'-deoxyadenosine
-
-
0.04
2'-deoxyadenosine
-
pleural fluid large isozyme
0.042
2'-deoxyadenosine
-
blood serum large isozyme
0.05 - 0.07
2'-deoxyadenosine
-
-
0.052
2'-deoxyadenosine
-
-
0.053
2'-deoxyadenosine
-
-
0.057
2'-deoxyadenosine
-
-
0.135
2'-deoxyadenosine
-
spleen small isozyme
0.189
2'-deoxyadenosine
-
lung small isozyme
0.2
2'-deoxyadenosine
-
-
0.22
2'-deoxyadenosine
-
-
0.333
2'-deoxyadenosine
-
-
0.4
2'-deoxyadenosine
-
-
0.56
2'-deoxyadenosine
-
37°C, pH not specified in the publication
0.0044
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.0087
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.0095
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.022
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.0306
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, wild-type enzyme
0.04461
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme C27Q/L227I
0.05256
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme L179H
0.115
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.20034
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme T174A
0.22422
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176A/L179A
0.25326
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176M
0.26747
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme T174I
0.28928
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176A
0.37605
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme F136L
0.000023
adenosine
-
-
0.00943
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme T174I
0.0147
adenosine
-
pH 7.5, 25°C
0.01728
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme, wild-type enzyme (refolded)
0.01784
adenosine
pH 8.0, temperature not specified in the publication, wild-type enzyme
0.02064
adenosine
pH 8.0, temperature not specified in the publication, wild-type enzyme
0.021
adenosine
-
at pH 7.4 and 37°C
0.02113
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme L179H
0.02344
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme C27Q/L227I
0.026
adenosine
-
25°C, 50 mM Tris-HCl buffer, pH 7.4, enzyme concentration 1.5 nM
0.029
adenosine
-
type 2-1
0.029
adenosine
-
37°C, pH not specified in the publication
0.032
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.03874
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme M155A
0.041
adenosine
-
pH 7.4, 37°C
0.04203
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme T174A
0.053
adenosine
-
blood serum large isozyme
0.055 - 0.07
adenosine
-
-
0.056
adenosine
-
kidney cortex large isozyme
0.05641
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme M155A (refolded)
0.057
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.06
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.07
adenosine
-
pleural fluid large isozyme
0.071
adenosine
-
wild-type, pH 7.5, 37°C
0.072
adenosine
pH and temperature not specified in the publication, mutant enzyme Y136R
0.083
adenosine
-
mutant enzyme D172E, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.087
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.088
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.093
adenosine
-
spleen small isozyme
0.104
adenosine
-
mutant enzyme D172A, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.12
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.12628
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176A
0.129
adenosine
-
lung small isozyme
0.15
adenosine
pH and temperature not specified in the publication, wild-type enzyme
0.15
adenosine
pH and temperature not specified in the publication, mutant enzyme E150R
0.15897
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176A/L179A
0.19
adenosine
-
membrane-bound ADA
0.22
adenosine
-
pH 7.4, 37°C
0.22
adenosine
-
soluble fraction
0.29961
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176M
0.32206
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme F136L
0.5
adenosine
-
pH 7.5, 37°C, ADAII
0.734
adenosine
-
pH 6.8, 37°C
1
adenosine
-
pH 7.2, 37°C, ADAII
1.13
adenosine
-
pH 7.5, 37°C, Vmax is 2.61 nmol NH3/min/mg protein
additional information
additional information
-
kinetics
-
additional information
additional information
thermodynamics and kinetics
-
additional information
additional information
-
thermodynamics and kinetics
-
additional information
additional information
-
isozymes ADA1 and ADA2 are kinetically distinct
-
additional information
additional information
-
kinetics of the large and the small isozyme
-
additional information
additional information
-
kinetics of the large and the small isozyme
-
additional information
additional information
-
optimization of a spectrometric kinetic measurement method pure enzyme, kinetics in presence of substrate, product and inhibitor, overview
-
additional information
additional information
-
optimization of a spectrometric kinetic measurement method using Hut78 cell extract, kinetics in presence of substrate, product and inhibitor, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.13 - 14.07
5'-methylthioadenosine
0.13
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.31
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.33
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme T174I
0.35
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.51
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.69
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme F136L
1.75
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176A/L179A
1.78
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176M
4.48
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme T174A
5.49
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176A
5.8
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
12.17
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme C27Q/L227I
13.92
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, wild-type enzyme
14.07
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme L179H
0.005
adenosine
-
0.31
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176A/L179A
0.97
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176M
1.31
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme F136L
1.8
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
1.9
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
2.42
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme T174I
4.1
adenosine
pH 8.0, temperature not specified in the publication, wild-type enzyme
4.41
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme L179H
4.7
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
5.3
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
5.35
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme M155A (refolded)
5.59
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176A
5.6
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
6.16
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme C27Q/L227I
6.8
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
7.45
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme T174A
11.5
adenosine
-
37°C, pH not specified in the publication
12.9
adenosine
-
mutant enzyme D172E, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
14
adenosine
-
mutant enzyme D172A, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
18.5
adenosine
-
pH 7.5, 25°C
28.69
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme M155A
40.71
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme, wild-type enzyme (refolded)
80.04
adenosine
pH 8.0, temperature not specified in the publication, wild-type enzyme
110
adenosine
pH and temperature not specified in the publication, wild-type enzyme
110
adenosine
pH and temperature not specified in the publication, mutant enzyme E150R
140
adenosine
pH and temperature not specified in the publication, mutant enzyme Y136R
180
adenosine
-
25°C, 50 mM Tris-HCl buffer, pH 7.4, enzyme concentration 1.5 nM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1 - 450
5'-methylthioadenosine
1
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme T174I
2
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme F136L
7
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176M
8
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176A/L179A
14
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
20
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176A
20
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme T174A
23
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
36
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
50
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
79
5'-methylthioadenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
270
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme C27Q/L227I
270
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, mutant enzyme L179H
450
5'-methylthioadenosine
pH 8.0, temperature not specified in the publication, wild-type enzyme
2
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176A/L179A
3
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176M
4
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme F136L
30
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
40
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme D176A
57
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
59
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
61
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
64
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
82
adenosine
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
90
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme M155A (refolded)
130
adenosine
-
mutant enzyme D172A, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
150
adenosine
-
mutant enzyme D172E, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
180
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme T174A
210
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme L179H
230
adenosine
pH 8.0, temperature not specified in the publication, wild-type enzyme
260
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme C27Q/L227I
260
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme T174I
740
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme M155A
750
adenosine
pH and temperature not specified in the publication, wild-type enzyme
750
adenosine
pH and temperature not specified in the publication, mutant enzyme E150R
2360
adenosine
pH 8.0, temperature not specified in the publication, mutant enzyme, wild-type enzyme (refolded)
2900
adenosine
pH and temperature not specified in the publication, mutant enzyme Y136R
3880
adenosine
pH 8.0, temperature not specified in the publication, wild-type enzyme
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0000022
(+)-erythro-9-(2-hydroxy-3-nonyl)adenine
pH 7.0, temperature not specified in the publication
0.00000011
(2S,3R)-3-(6-amino-9H-purin-9-yl)-5-[3-(trifluoromethyl)phenyl]pentan-2-ol
pH 7.0, temperature not specified in the publication
0.0000052
(2S,3R)-3-(6-amino-9H-purin-9-yl)-5-[4-(trifluoromethyl)phenyl]pentan-2-ol
pH 7.0, temperature not specified in the publication
0.0009 - 0.0019
(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol
0.00186
1-(4-benzylphenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea
30°C, pH 7.12
0.0000115
1-(4-fluorophenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea
30°C, pH 7.9
0.0002827
1-(4-methoxyphenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea
30°C, pH 7.8
0.000857
1-benzyl-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea
30°C, pH 7.14
0.0004 - 0.0012
1-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
0.0016 - 0.0074
1-deazaadenosine
0.000077
1-[(1R)-1-(hydroxymethyl)-3-(6-[[(1-methyl-1H-benzimidazol-2-yl)acetyl]amino]-1H-indol-1-yl)propyl]-1H-imidazole-4-carboxamide
-
0.0068
1-[(1R)-1-(hydroxymethyl)-3-naphthalen-1-ylpropyl]-1H-imidazole-4-carboxamide
-
0.059
1-[(1R)-1-(hydroxymethyl)-3-phenylpropyl]-1H-imidazole-4-carboxamide
-
0.54
1-[(1R)-2-hydroxy-1-phenylethyl]-1H-imidazole-4-carboxamide
-
0.013
1-[(1R)-3-[6-(acetylamino)-1H-indol-1-yl]-1-(hydroxymethyl)propyl]-1H-imidazole-4-carboxamide
-
0.00024
1-[(1R)-3-[6-(hexanoylamino)-1H-indol-1-yl]-1-(hydroxymethyl)propyl]-1H-imidazole-4-carboxamide
-
0.00011
1-[(1R,2S)-2-hydroxy-1-(2-naphthalen-1-ylethyl)propyl]-1H-imidazole-4-carboxamide
-
0.0000059
1-[(3R,4S)-4-hydroxy-1-[3-(trifluoromethyl)phenyl]pentan-3-yl]-1H-imidazole-4-carboxamide
pH 7.0, temperature not specified in the publication
0.000026
1-[(R)-1-hydroxy-4-(1-methyl-5-(3-phenylpropoxy)indol-3-yl)-2-butyl]imidazole-4-carboxamide
-
0.0019
1-[(R)-1-hydroxy-4-(5-(3-phenylpropoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
0.000011
1-[(R)-1-hydroxy-4-(6-(3-(1-methylbenzimidazol-2-yl)propionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
0.000017
1-[(R)-1-hydroxy-4-(6-(3-(3-pyridyl)propionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
0.000057
1-[(R)-1-hydroxy-4-(6-(3-(4-methoxyphenyl)propionylamino)indol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
0.000038
1-[(R)-1-hydroxy-4-(6-(3-(4-methylphenyl)propionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
0.00003
1-[(R)-1-hydroxy-4-(6-(3-phenylpropionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
0.000017
1-[(R)-1-hydroxy-4-(6-(3-phenylpropoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
0.000034
1-[(R)-1-hydroxy-4-(6-(4-(4-methylphenyl)butyrylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
0.000012
1-[(R)-1-hydroxy-4-(6-(4-phenylbutoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
0.000016
1-[(R)-1-hydroxy-4-(6-(4-phenylbutyrylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
0.0000077
1-[(R)-1-hydroxy-4-(6-(5-phenylvalerylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
0.000091
1-[(R)-1-hydroxy-4-(6-(6-phenylhexanoylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide
-
0.0000049
1-[(R)-4-(5-(3-(4-chlorophenyl)propoxyl)-1-methylindol-3-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
0.000013
1-[(R)-4-(5-hexyloxy-1-methylindol-3-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
0.0062
1-[(R)-4-(5-hexyloxyindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
0.000013
1-[(R)-4-(6-(3-(4-chlorophenyl)propoxy)indol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
0.0000075
1-[(R)-4-(6-(3-benzylureido)indol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
0.0013
1-[(R)-4-(6-acetylaminoindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
0.00024
1-[(R)-4-(6-butoxyindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
0.000024
1-[(R)-4-(6-hexanoylaminoindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
0.000055
1-[(R)-4-(6-hexyloxyindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide
-
0.0000201
1-[4-(dimethylamino)phenyl]-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea
30°C, pH 7.11
0.00108
1-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-3-(4-phenoxyphenyl)urea
30°C, pH 7.13
0.0000242
1-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-3-phenylurea
30°C, pH 7.7
0.0000016
1-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-3-[4-(trifluoromethyl)phenyl]urea
30°C, pH 7.10
0.0121
2'-deoxy-4-amino-1-(beta-D-ribofuranosyl)-3H-imidazo[4,5-d]pyridazin-7-(6H)-one
-
pH 7.4, 25°C
0.052
2'-deoxy-7-amino-1-(beta-D-ribofuranosyl)-1H-imidazo[4,5-d]pyridazin-4-(5H)-one
-
pH 7.4, 25°C
0.0000034
2'-deoxycoformycin
-
37°C, pH not specified in the publication
0.33
2-Aminopurine
-
pH 7.5, 25°C
0.000025 - 0.00012
3-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
0.52 - 1
3-deazaadenosine
0.000066
4-amino-1-(2-hydroxy-3-nonyl)pyrazolo[3,4d]pyrimidine
-
pH 7.2, 30°C
0.0106
4-amino-1-(beta-D-ribofuranosyl)-3H-imidazo[4,5-d]pyridazin-7-(6H)-one
-
pH 7.4, 25°C
0.00462
4-amino-1-(beta-hydroxyethyl)pyrazolo[3,4d]pyrimidine
-
pH 7.2, 30°C
1.8
4-aminopyridine
-
pH 7.5, 25°C
1.3
4-aminopyrimidine
-
pH 7.5, 25°C
0.0000096
4-fluoro-N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]benzamide
30°C, pH 7.4
1.4
4-hydroxypyridine
-
pH 7.5, 25°C
0.0001556
4-methoxy-N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]benzamide
30°C, pH 7.3
0.00000079
5'-methylthio-2'-deoxycoformycin
-
-
0.00000043 - 0.029
5'-methylthiocoformycin
0.0265
5-carbamimidoyl-1-(beta-D-ribofuranosyl)-1H-imidazole-4-carbohydrazide
-
pH 7.4, 25°C
0.012
7,8-dihydro-1-p-methoxybenzyl-6H-6,7-dimethyl-8-propoxyimidazo[4,5-e][1,2,4]-triazepine
-
pH 7.0, 25°C
0.023
7,8-dihydro-1-p-methoxybenzyl-8-(2-methoxyethoxy)-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
pH 7.0, 25°C
0.093
7,8-dihydro-1-p-methoxybenzyl-8-(3-methylbenzyloxy)-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
pH 7.0, 25°C
0.077
7,8-dihydro-1-p-methoxybenzyl-8-(4-methoxybenzyloxy)-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
pH 7.0, 25°C
0.02
7,8-dihydro-8-ethoxy-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
pH 7.0, 25°C
0.03
7,8-dihydro-8-isopropoxy-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
pH 7.0, 25°C
0.024
7,8-dihydro-8-methoxy-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
pH 7.0, 25°C
0.0514
7-amino-1-(beta-D-ribofuranosyl)-1H-imidazo[4,5-d]pyridazin-4-(5H)-one
-
pH 7.4, 25°C
0.015
8-butoxy-7,8-dihydro-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine
-
pH 7.0, 25°C
0.126 - 0.214
acetaminophen
0.0428 - 0.0968
Acetylsalicylic acid
0.17
adenine
-
pH 7.5, 25°C
0.00000025
coformycin
-
37°C, pH not specified in the publication
0.0000015 - 0.000014
D-coformycin
0.00009 - 0.01
diethyl dicarbonate
0.00011 - 0.00014
erythro-9-(2-hydroxy-3-nonyl)-3-deazaadenine
0.00007 - 0.00008
erythro-9-(2-hydroxy-3-nonyl)-adenine
0.00000114 - 0.0005
erythro-9-(2-hydroxy-3-nonyl)adenine
0.35
Inosine
-
pH 7.5, 25°C
0.000478
N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-2-phenylacetamide
30°C, pH 7.6
0.000051
N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-4-(trifluoromethyl)benzamide
30°C, pH 7.5
0.0001265
N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]benzamide
30°C, pH 7.2
0.018
N6-methyladenosine
-
25°C, 50 mM Tris-HCl buffer, pH 7.4, enzyme concentration 1.5 nM
0.25
phenylhydrazine
-
pH 7.5, 25°C
1.1
purine
-
pH 7.5, 25°C
0.008 - 0.016
purine riboside
additional information
additional information
-
0.0009
(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol
-
mutant D172A, pH 7.5, 30°C
0.0019
(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol
-
wild-type, pH 7.5, 30°C
0.0004
1-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
kidney cortex large isozyme
0.00045
1-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
pleural fluid large isozyme
0.0006
1-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
blood serum large isozyme
0.0011
1-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
spleen small isozyme
0.0012
1-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
lung small isozyme
0.0016
1-deazaadenosine
-
kidney cortex large isozyme
0.0025
1-deazaadenosine
-
pleural fluid large isozyme
0.0029
1-deazaadenosine
-
blood serum large isozyme
0.0029
1-deazaadenosine
-
lung small isozyme
0.0057
1-deazaadenosine
-
spleen small isozyme
0.007
1-deazaadenosine
-
pH 7.1, 23°C
0.0074
1-deazaadenosine
-
pH 7.1, 23°C, after preincubation with diethyl dicarbonate
0.000025
3-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
blood serum large isozyme
0.000036
3-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
pleural fluid large isozyme
0.00005
3-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
kidney cortex large isozyme
0.00011
3-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
spleen small isozyme
0.00012
3-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine
-
lung small isozyme
0.52
3-deazaadenosine
-
blood serum large isozyme
0.69
3-deazaadenosine
-
kidney cortex large isozyme
0.81
3-deazaadenosine
-
lung small isozyme
1
3-deazaadenosine
-
above, pleural fluid large isozyme
1
3-deazaadenosine
-
above, spleen small isozyme
0.00000043
5'-methylthiocoformycin
-
-
0.0000032
5'-methylthiocoformycin
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.000014
5'-methylthiocoformycin
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.00002
5'-methylthiocoformycin
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.00003
5'-methylthiocoformycin
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.000048
5'-methylthiocoformycin
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.029
5'-methylthiocoformycin
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.126
acetaminophen
-
pH 7.5, 27°C
0.214
acetaminophen
-
pH 7.5, 37°C
0.0428
Acetylsalicylic acid
-
pH 7.5, 27°C
0.0968
Acetylsalicylic acid
-
pH 7.5, 37°C
0.0000015
D-coformycin
-
mutant enzyme D172E, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.0000018
D-coformycin
-
mutant enzyme D172A, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.0000023
D-coformycin
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.0000034
D-coformycin
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.0000047
D-coformycin
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.000007
D-coformycin
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.0000074
D-coformycin
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.000014
D-coformycin
-
wild type enzyme, in 100 mM Tris-HCl buffer (pH 8.0), temperature not specified in the publication
0.03
diclofenac
-
pH 7.5, 37°C
0.0564
diclofenac
-
pH 7.5, 27°C
0.00009
diethyl dicarbonate
-
pH 7.1, 23°C, in presence of 0.022 mM erythro-9-(2-hydroxy-3-nonyl)-adenine
0.00013
diethyl dicarbonate
-
pH 7.1, 23°C, in presence of 0.03 mM erythro-9-(2-hydroxy-3-nonyl)-3-deazaadenine
0.01
diethyl dicarbonate
-
pH 7.1, 23°C, in presence of 0.008 mM 1-deazaadenosine
0.00011
erythro-9-(2-hydroxy-3-nonyl)-3-deazaadenine
-
pH 7.1, 23°C, after preincubation with diethyl dicarbonate
0.00014
erythro-9-(2-hydroxy-3-nonyl)-3-deazaadenine
-
pH 7.1, 23°C
0.00007
erythro-9-(2-hydroxy-3-nonyl)-adenine
-
pH 7.1, 23°C, after preincubation with diethyl dicarbonate
0.00008
erythro-9-(2-hydroxy-3-nonyl)-adenine
-
pH 7.1, 23°C
0.00000114
erythro-9-(2-hydroxy-3-nonyl)adenine
-
pH 7.2, 30°C
0.0000114
erythro-9-(2-hydroxy-3-nonyl)adenine
30°C, pH 7.15
0.000021
erythro-9-(2-hydroxy-3-nonyl)adenine
-
kidney cortex large isozyme
0.00003
erythro-9-(2-hydroxy-3-nonyl)adenine
-
pleural fluid large isozyme
0.00004
erythro-9-(2-hydroxy-3-nonyl)adenine
-
lung small isozyme
0.000057
erythro-9-(2-hydroxy-3-nonyl)adenine
-
spleen small isozyme
0.00006
erythro-9-(2-hydroxy-3-nonyl)adenine
-
blood serum large isozyme
0.0005
erythro-9-(2-hydroxy-3-nonyl)adenine
-
pH 7.4, 37°C
0.008
purine riboside
-
25°C, 50 mM Tris-HCl buffer, pH 7.4, enzyme concentration 1.5 nM
0.016
purine riboside
-
pH 7.5, 25°C
additional information
additional information
-
inhibition kinetics
-
additional information
additional information
-
the adenine moiety of inhibitors does not bind to the histidine residues of the active site His238
-
additional information
additional information
-
inhibition kinetics of the large and the small isozyme
-
additional information
additional information
-
inhibition kinetics of the large isozyme
-
additional information
additional information
-
kinetics and thermodynamic effects of inhibitors, QSAR analysis, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.009
-
liver, cerebellum, spinal cord
0.027
-
pancreas, cerebrum
0.06
-
substrate 2,3-O-isopropylidene adenosine, pH 4.0
0.076
-
membrane-bound enzyme
0.136
-
membrane-bound enzyme
0.164
-
membrane-bound enzyme
0.191
Staphylococcus aerogenes
-
membrane-bound enzyme
0.2
-
substrate adenosine, pH 4.0
0.281
Micrococcus candidus
-
membrane-bound enzyme
0.366
-
membrane-bound enzyme
0.401
-
membrane-bound enzyme
0.45
-
purified large isozyme from blood serum
0.475
-
T cell line CCRF-HSB-2
0.501
-
T cell line CCRF-CEM
0.6
-
substrate 2,3-O-isopropylidene adenosine, pH 6.0
0.622
-
membrane-bound enzyme
0.65
-
purified large isozyme from pleural fluid
0.8
-
substrate 2,3-O-isopropylidene adenosine, pH 8.0
0.965
-
T cell line RPMI-8402
1.064
-
T cell line MOLT-4
1.1
-
substrate adenosine, pH 8.0
1.2
-
purified isozyme ADA2
1.28
Micrococcus freudenreichii
-
membrane-bound enzyme
1.32
-
enzyme at day 9 of embryogenesis
1.99
-
enzyme at the first day of embryogenesis
10.5
Micrococcus candidus
-
soluble enzyme
120
-
crude cell extract, pH 7.5, temperature not specified in the publication
166
purified isozyme ADA2
19.1
Micrococcus freudenreichii
-
soluble enzyme
2
enzymatic data, conformational properties and docking scores for adenosine analogue 2,3-O-methoxymethylideneadenosine, modeling studies
2.16
-
enzyme at day 24 of embryogenesis
2.2
-
protamine sulfate supernatant
2029
-
pH 6.8, 37°C, enzyme from hemolymph
2180
Micrococcus sodonensis
-
soluble enzyme
260
-
purine riboside Sepharose chromatography
271
Pseudomonas iodinum
-
-
350
-
purified small isozyme from lung and spleen
372
Micrococcus sodonensis
-
membrane-bound enzyme
4.4
-
partially purified ADAI
5.4
-
purified small isozyme from kidney cortex
52
-
Q Sepharose chromatography
60 - 130
-
purified commercial preparation from spleen
760
-
crude cell extract, pH 7.5, temperature not specified in the publication
834
-
pH 6.8, 25°C, enzyme from hemolymph
0.12
0.033 mM adenosine in 0.2 M phosphate buffer (pH 6.7), 30°C
0.5
-
substrate 2,3-O-isopropylidene adenosine, pH 5.0
0.5
-
substrate adenosine, pH 5.0
0.9
enzymatic data, conformational properties and docking scores for adenosine analogue 2,3-O-isopropylidenadenosine, modeling studies
0.9
-
substrate 2,3-O-isopropylidene adenosine, pH 7.0
1
substrate adenosine
1
-
substrate adenosine, pH 6.0
1
-
substrate adenosine, pH 7.0
additional information
no activity with substrate 9H-(1-deoxy-3,4-O-isopropylidene-beta-D-psicofuranosyl)adenine, adenosine deaminase aptly transforms substrates largely modified at the 2- and 3-O-positions, whereas C-modification at the 1-position prevents the adenosine deaminase-catalyzed deamination
additional information
-
the serum adenosine deaminase activity increases significantly in all infected groups compared to control group (adenosine deaminase activity: 5.99 IU/l control group, 27.62 IU/l infected group)
additional information
-
relative substrate specificity in nmol NH3/min/mg of protein, adenosine 11.2, 2-deoxyadenosine 23.6, guanosine 1.8, 2-deoxyguanosine 2.0 for the soluble fraction, adenosine 20.9, 2-deoxyadenosine 5.4, guanosine 1.7, 2-deoxyguanosine 1.8 for the membrane-bound adenosine deaminase
additional information
-
75.7 U/g tissue, ADAII
additional information
the adenosine deaminase activity level is highest at day 1 in all the regions of chicken gastrointestinal tract and could be reduced or enhanced by corticosterone and dibutyryl cAMP, respectively, in an age-specific manner
additional information
-
the adenosine deaminase activity level is highest at day 1 in all the regions of chicken gastrointestinal tract and could be reduced or enhanced by corticosterone and dibutyryl cAMP, respectively, in an age-specific manner
additional information
-
activity in cerebrospinal fluid of healthy persons and tuberculous or non-infectious meningitis patients
additional information
-
enzyme activity in nasal polyps and nasal mucosa
additional information
-
enzyme activity in T-lymphocytes of healthy persons and multiple sclerosis patients
additional information
-
patients with fever attack have significantly higher adenosine deaminase levels in plasma compared to attack-free periods and healthy control group
additional information
-
tADA and ADA2 levels are higher in patients with Chronic Granulomatous Disease (CGD), Leukocyte Adhesion Deficiency (LAD), hyper IgM (HIM) and Wiskott-Aldrich Syndrome (WAS) than those of corresponding controls. There is a significant elevation of tADA and ADA1 activities in IgA deficiency patients as compared to healthy individuals
additional information
-
adenosine deaminase activity is higher in young rat brains when compared to the 60-day-old rats and is higher in hippocampus when compared to the cerebral cortex
additional information
326 nkat/mg with substrate adenine, reaction of EC 3.5.4.2, adenine deaminase
additional information
-
326 nkat/mg with substrate adenine, reaction of EC 3.5.4.2, adenine deaminase
additional information
-
ADA activity is observed in the parasites at all concentrations tested and its activity is proportional to the concentration of protein, ranging between 0.64 and 2.24 U/l in the lowest and highest concentration of protein, respectively
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
commercial enzyme preparation at 20 mg/ml, native enzyme or complexed with inhibitor purine riboside, sitting drop vapour diffusion method, micro-stirring technique over 2 weeks, from 2.2 M ammonium sulfate, 2% 2-methyl-2,4-pentanediol, 0.1 M MES, pH 6.0, 20°C, with reservoir solution containing 20% 2-propanol, 20% PEG 4000, 0.1 M citrate, pH 5.6, X-ray diffraction structure determination and analysis at 1.8 A resolution
-
crystal structure of adenosine deaminase ligated with (+)-erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), vapor diffusion, sitting drop, 2 M ammonium sulfate, 2% 2-methyl-2, 4-pentanediol, 0.1 M MES buffer, pH 6.0, temperature 293K, , X-ray diffraction structure determination and analysis at 2.52 A resolution, space group P 43 21 2, EHNA induces conformational change of adenosine deaminase to the open form in the crystalline state, structural comparison between the EHNA-ADA complex and the 1-eaza-adenosine-ADA complex
crystals of the complex of adenosine deaminase with 6-hydroxy-1,6-dihydropurine riboside are grown against reservoirs containing 2.0-2.2 M ammonium sulfate, 2% v/v polyethylene glycol 400 in 0.1 M HEPES buffer, pH 7.5, solved at 2.5 A resolution
-
molecular modeling enzyme-inhibitor, docking simulations enzyme-inhibitor, drug design
purified intestinal enzyme complexed with 1-[(R)-1-hydroxy-4-(6-(5-phenylvalerylamino)indol-1-yl)2-butyl]imidazole-4-carboxamide, 1-[(R)-1-hydroxy-4-(6-(3-phenylpropionylamino)indol-1-yl)2-butyl]imidazole-4-carboxamide, or 1-[(R)-4-(6-(3-benzylureido)indol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide, protein solution is mixed with precipitant solution containing 100 mM MES, pH 6.0, 2.1 ammonium sulfate, and 2.5% v/v PEG 400, X-ray diffraction structure determination and analysis at 2.2 A resolution
holo- and apo-ADA, hanging drop vapor diffusion method, using 20% (w/v) PEG 3350 and 200 mM ammonium sulfate, pH 4.7 for apo-ADA or 25% (w/v) PEG 6000, 20 mM Tris-HCl and pH 8.5 for holo-ADA
the binding free energies of a series of adenosine deaminase inhibitors are calculated, and the structure-activity relationship is investigated, the inhibitor recognition mechanism of adenosine deaminase and the effect of methyl substitution in inhibitors are discussed on the basis of the analysis of MD trajectories
crystal structure of a surface engineered adenosine deaminase at a resolution of 2.48 A
crystal structure of adenosine deaminase from Plasmodium vivax in complex with inhibitor, 2-deoxycoformycin (pentostatin), 33% PEG 20000, 0.1 M TAPS (pH 9.0), 0.1 M Sodium phosphate (monobasic), 16% acetonitrile, 5 mM adenosine, pH 7.0, vapor diffusion, sitting drop, temperature 298K, space group C 2 2 21, X-ray diffraction structure determination and analysis at 2.3 A resolution, molecular modeling, crystal structure of adenosine deaminase from Plasmodium vivax in complex with adenosine, space group C 2 2 21, X-ray diffraction structure determination and analysis at 1.89 A resolution, crystal structure of adenosine deaminase from Plasmodium vivax in complex with guanosine, 27.3% PEG 20000, 0.1 M CHES (pH 9.5), 0.1 M Sodium phosphate monobasic, 5 mM guanosine, vapor diffusion, sitting drop, temperature 293K, space group C 2 2 21, X-ray diffraction structure determination and analysis at 2.19 A resolution, these structures highlight a drastic conformational change in plasmodial adenosine deaminase upon substrate binding, these complexes illuminate the structural basis for the differential substrate specificity and potential drug selectivity between mammalian and parasite enzymes
Plasmodium vivax ADA in a complex with 5'-methylthiocoformycin is crystallized by the sitting drop vapor diffusion method, using 25% (w/v) PEG3350, 100 mM HEPES (pH 7.5), and 0.2 M MgCl2
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pharmacology
-
Plasmodium falciparum-specific inhibitors of adenosine deaminase have potential for development as antimalarials without inhibition of host enzyme
analysis
-
a capillary electrophoresis method for simultaneous analysis of adenosine deaminase in red blood cells is developed. The method is also successfully applied in the inhibitor screening from traditional Chinese medicines
analysis
analysis of adenosine deaminase in saliva could be used as a simple, rapid, economic and non-invasive diagnostic tool in porcine production in field conditions
diagnostics
-
the enzym elevle is a useful biochemical parameter for assessing the functional status of liver of sheep with chronicle fascioliasis
diagnostics
-
adenosine deaminase activity in pleural effusions due to Legionnaires disease may be as high as that in pleural effusions due to tuberculosis. In countries where the prevalence of tuberculosis is high and pleural fluid adenosine deaminase activities are frequently measured, Legionnaires disease should be included in the differential diagnosis of an exudative pleural effusion with a high ADA activity
diagnostics
-
adenosine deaminase analysis is a sensitive marker of tuberculous pleuritis even in HIV patients with very low CD4 counts in a high tuberculosis endemic region. The adenosine deaminase assay is inexpensive, rapid, and simple to perform and is of great value for the immediate diagnosis of tuberculous pleuritis while waiting for culture result and this has a positive impact on patient outcome
diagnostics
-
adenosine deaminase is a very useful biochemical parameter in diagnostic analysis tuberculous pleural effusion. When combined with cytologic examination the results are even better
diagnostics
-
adenosine deaminase may be used as a supportive marker to differentiate familial mediterranean fever attacks from attack-free periods
diagnostics
-
increased serum adenosine deaminase activity in tropical theileriosis may reflect the involvement of the cellular immune responses
diagnostics
-
serum tADA and ADA2 may serve as useful indicators for diagnosis of CGD, LADs, IgA deficiency, SCID, HIM and WAS patients as a supplementary laboratory test in combination with clinical, immunological, and other laboratory findings
diagnostics
-
adenosine deaminase activity is significantly higher in patients with renal cell carcinoma than in controls. The marker adenosine deaminase might be potentially important as an additional biochemical tool for diagnosing renal cell carcinoma
diagnostics
analysis of adenosine deaminase in saliva could be used as a simple, rapid, economic and non-invasive diagnostic tool in porcine production in field conditions
drug development
-
enzyme inhibitor FR234938 might be effective as an anti-rheumatic and anti-inflammatory drug by modulating the host-defense concentrations of adenosine
drug development
adenosine deaminase inhibitors have potential as anti-inflammatory drugs or immunosuppressants
drug development
-
because these enzyme plays an important role in nucleotide metabolism, they are relevant targets in anticancer and antibacterial therapies
drug development
Plasmodium parasites lack enzymes critical for de novo purine synthesis and thus rely on purine salvage to supply precursors for nucleic acid synthesis and energy metabolism. Thus, the purine salvage pathway is an attractive drug target
drug development
-
progesterone treatment may prevent epileptic activity by decreasing adenosine deaminase levels
medicine
-
therapy for adenosine-deficient patients with combined immunodeficiency
medicine
-
therapy for adenosine-deficient patients with combined immunodeficiency
medicine
genetic polymorphisms of adenosine receptors A1 and A2A are associated with aspirin-intolerant asthma, suggesting that adenosine might play a crucial role in the development of aspirin-intolerant asthma through interactions with the A1 and A2A receptors. In this study no association between ADA and aspirin-intolerant asthma development is found
medicine
-
the adenosine deaminase-adenosine pathway plays a significant role in hemolytic-anemia-associated pulmonary hypertension, and modulation of this pathway may offer protective/therapeutic effects in hemolysis-associated pulmonary hypertension, in particular, under conditions of severe NO deficiency/NO resistance
medicine
-
ADA is an adjuvant for a dendritic cell-based vaccine against HIV. ADA potentiates human T-lymphocyte proliferation 4.5fold in co-cultures of HIV-inactivated-pulsed dendritic cells and autologous T cells of HIV-1-infected individuals. ADA enhances cytokine secretion in co-cultures of HIV-pulsed dendritic cells with T cells
medicine
ADA2 is a drug candidate to modulate the immune responses during inflammation and cancer. ADA2 and its inhibitors are drug candidates to activate the immune systems of immunocompromised patients and to treat various types of blood cancers
medicine
-
the mean values for total ADA and ADA2 activities in the serum and tumor of benign breast disease and breast cancer are significantly higher than those of healthy controls
medicine
-
the adenosine deaminase activity in the cerebrospinal fluid is a good tool for early initiation of anti-tuberculous therapy while waiting for definite confirmation. A simple algorithm is identified that combines adenosine deaminase activity and some readily available biochemical parameters in cerebrospinal fluid, adenosine deaminase above 11.5 U/l + glucose above 65 mg/dl + leukocytes aboved 13.5 cell/mm3, as the better predictor to guide prompt initiation of anti-tuberculous therapy and should be considered in patients with low prevalence of tuberculosis
medicine
-
therapy for adenosine-deficient patients with combined immunodeficiency
-